Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|5|642-651

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.5, 2014-03, pp. : 642-651

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 139, Iss. 10, 2016-11 ,pp. : 2336-2342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-10 ,pp. : 740-745

Karger

Access to resources Recommend Favorite

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

By  

Oncology Research and Treatment, Vol. 34, Iss. 5, 2011-04 ,pp. : 233-238

Karger

Access to resources Recommend Favorite

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

By  

Case Reports in Oncology, Vol. 6, Iss. 3, 2013-09 ,pp. : 450-455

Karger

Access to resources Recommend Favorite